Expanding use of anti-epileptic therapy: Implications on bone disease

Therapy

Volumn 4, Issue 1, 2007, Pages 79-89

  Arora, Surender K ^a   Bubb, Chard ^a   Karam, Jocelyne ^a   McFarlane, Samy I ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Anti epileptics; Bone densitometry; Osteoporosis; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANTACID AGENT; ANTIANDROGEN; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBAMAZEPINE; CLONAZEPAM; COLESTYRAMINE; CYCLOSPORIN A; GLUCOCORTICOID; GONADORELIN; HEPARIN; HORMONE DERIVATIVE; IBANDRONIC ACID; LAMOTRIGINE; METHOTREXATE; OXCARBAZEPINE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHENOBARBITAL; PREGNANE X RECEPTOR; RISEDRONIC ACID; SEX HORMONE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; VITAMIN K GROUP; ZONISAMIDE;

ALCOHOL WITHDRAWAL; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DENSITY; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM METABOLISM; DEMENTIA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FALLING; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE COST; HIGH RISK POPULATION; HORMONE RESISTANCE; HUMAN; IMMOBILIZATION; MENTAL DISEASE; MORBIDITY; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COUNSELING; PATIENT MONITORING; PHOTOSENSITIVITY; POSTMENOPAUSE; RASH; RECEPTOR UPREGULATION; RECOMMENDED DRUG DOSE; REVIEW; RICKETS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SMOKING CESSATION; STEROIDOGENESIS; SUN EXPOSURE; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY;

EID: 33847328309     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.1.79     Document Type: Review

References (72)

1. Scott RA, Lhatoo SD, Sander JW: The treatment of epilepsy in developing countries: where do we go from here? Bull. WHO 79. 344-351 (2001).
2. Lackner TE: Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy 22, 329-364 (2002).
3. Ali II, Schuh L, Barkley GL. Gates JR: Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav. 5, 296-300 (2004).
4. Sheth RD: Metabolic concerns associated with antiepileptic medications. Neurology 63, S24-S29 (2004).
5. Pack AM, Gidal B, Vazquez B: Bone disease associated with antiepileptic drugs. Cleve. Clin. J. Med. 71 (Suppl. 2), S42-S48 (2004).
6. Pack AM, Morrell MJ: Epilepsy and bone health in adults. Epilepsy Behav. 5(Suppl. 2). S24-S29 (2004).
7. Valsamis HA, Arora SK, Labban B, McFarlane SI: Antiepileptic drugs and bone metabolism. Nutr. Metab. (Lond.) 3, 36 (2006).
8. Fitzpatrick LA: Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav. 5(Suppl. 2), S3-S15 (2004).
9. Valmadrid C, Voorhees C, Litt B, Schneyer CR: Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch. Neurol. 58, 1369-1374 (2001).
10. Holick M, Krane SM: Introduction to bone and mineral metabolism. In: Harrison's Principles of Internal Medicine (15th Edition). McGraw-Hill, NY, USA (2001).
11. Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L: Fracture risk is increased in epilepsy. Acta Neurol. Scand. 99, 269-275 (1999).
12. Mattson RH, Gidal BE: Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav. 5(Suppl. 2), S36-S40 (2004).
13. Lidgren L, Walloe A: Incidence of fracture in epileptics. Acta Orthop. Scand. 48, 356-361 (1977).
14. Neufeld MY, Vishne T, Chistik V, Korczyn AD: Life-long history of injuries related to seizures. Epilepsy Res. 34, 123-127 (1999).
15. Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of antiepileptic drugs. Epilepsia 45, 1330-1337 (2004).
16. National Osteoporosis Foundation, American Academy of Orthopedic Surgeons: Physician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington DC, USA (1998).
17. Baran DT: Seconday causes of osteoporosis: thyrotoxicosis and lack of weight bearing. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (5th Edition). American Society for Bone and Mineral Research, Washington DC, USA (2003).
18. Leidy NK, Elixhauser A, Vickrey B, Means E, Willian MK: Seizure frequency and the health-related quality of life of adults with epilepsy. Neurology, 53, 162-166 (1999).
19. Holick MF: Vitamin D: Photobiology, metabolism, mechanism of action, and clinical application. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (5th Edition). American Society for Bone and Mineral Research, Washington DC, USA (2003).
20. Kruse R: [Osteopathies in antiepileptic long-term therapy (preliminary report)]. Monatsschr. Kinderheilkd 116, 378-381 (1968).
21. Hahn TJ: Bone complications of anticonvulsants. Drugs 12, 201-211 (1976).
22. Tsukahara H, Kimura K, Todoroki Y et al.: Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr. Int. 44, 247-253 (2002).
23. van Doom C, Gruber-Baldini AL, Zimmerman S et al.: Dementia as a risk factor for falls and fall injuries among nursing home residents. J. Am. Geriatr. Soc. 51, 1213-1218 (2003).
24. Sato Y, Kondo I, Ishida S et al.: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57, 445-449 (2001).
25. Wallace C, Reiber GE, LeMaster J et al.: Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care 25, 1983-1986 (2002).
26. Keegan TH, Kelsey JL, Sidney S, Quesenberry CP Jr: Foot problems as risk factors of fractures. Am. J. Epidemiol. 155, 926-931 (2002).
27. Desai KB, Ribbans WJ, Taylor GJ: Incidence of five common fracture types in an institutional epileptic population. Injury 27, 97-100 (1996).
28. Cummings SR, Nevitt MC, Browner WS et al.: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332, 767-773 (1995).
29. Ensrud KE, Blackwell TL, Mangione CM et al.: Central nervous system-active medications and risk for falls in older women. J. Am. Geriatr. Soc. 50, 1629-1637 (2002).
30. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL: Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62, 2051-2057 (2004).
31. Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB: Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J. Clin. Endocrinol. Metab. 58, 1003-1009 (1984).
32. Valimaki MJ, Tiihonen M, Laitinen K et al.: Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J. Bone Miner. Res. 9, 631-637 (1994).
33. Erbayat Altay E, Serdaroglu A, Tumer L, Gucuyener K, Hasanoglu A: Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J. Pediatr. Endocrinol. Metab. 13, 933-939 (2000).
34. Tjellesen L, Nilas L, Christiansen C: Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol. Scand. 68, 13-19 (1983).
35. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N: A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Q. J. Med. 59, 569-577 (1986).
36. Ecevit C, Aydogan A, Kavakli T, Altinoz S: Effect of carbamazepine and valproate on bone mineral density. Pediatr. Neurol. 31, 279-282 (2004).
37. Richens A, Rowe DJ: Disturbance of calcium metabolism by anticonvulsant drugs. Br. Med. J. 4, 73-76 (1970).
38. Kulak CA, Borba VZ, Bilezikian JP, Silvado CE, Paola L, Boguszewski CL: Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq. Neuropsiquiatr. 62, 940-948 (2004).
39. Kafali G, Erselcan T, Tanzer F: Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin. Pediatr. (Phila) 38, 93-8 (1999).
40. Hahn T, Hendin B, Scharp C. Boisseau V, Haddad J: Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N. Engl. J. Med. 292, 550-554 (1975).
41. Dent CE, Richens A, Rowe DJ, Stamp TC: Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br. Med. J. 4, 69-72 (1970).
42. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA: Long-term anticonvulsant therapy leads to low bone mineral density - evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp. Clin. Endocrinol. Diabetes 108, 37-43 (2000).
43. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G: Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58, 1348-1353 (2002).
44. Telci A, Cakatay U, Kurt BB et al.: Changes in bone turnover and deoxypyridinoline levels in epileptic patients. Clin. Chem. Lab. Med. 38, 47-50 (2000).
45. Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F: Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43, 1488-1492 (2002).
46. Verrotti A, Greco R, Morgese G, Chiarelli F: Increased bone turnover in epileptic patients treated with carbamazepine. Ann. Neurol. 47, 385-388 (2000).
47. Kruse K, Suss A, Busse M, Schneider P: Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J. Pediatr. 111, 57-63 (1987).
48. Oner N, Kaya M, Karasalihoglu S, Karaca H, Celtik C, Tutunculer F: Bone mineral metabolism changes in epileptic children receiving valproic acid. J. Paediatr. Child Health 40, 470-473 (2004).
49. Genant HK, Cooper C, Poor G et al.: Interim report and recommendations of the World Health Organization Task Force for Osteoporosis. Osteoporos. Int. 10, 259-264 (1999).
50. Andress DL, Ozuna J, Tirschwell D et al.: Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch. Neurol. 59, 781-786 (2002).
51. Guo CY, Ronen GM, Atkinson SA: Long-term valproate and lamotrigine, treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42, 1141-1147 (2001).
52. Sheth RD: Bone health in pediatric epilepsy. Epilepsy Behav. 5(Suppl. 2), S30-S35 (2004).
53. Sheth RD, Wesolowski CA, Jacob JC et al.: Effect of carbamazepine and valproate on bone mineral density. J. Pediatr. 127, 256-262 (1995).
54. Wolschendorf K, Vanselow K, Moller WD, Schulz H: A quantitative determination of anticonvulsant-induced bone demineralization by an improved x-ray densitometry technique. Neuroradiology 25, 315-318 (1983).
55. Pack AM, Morrell MJ, Marcus R et al.: Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann. Neurol. 57, 252-257 (2005).
56. Baran DT: Seconday causes of osteoporosis: thyrotoxicosis and lack of weight bearing. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (5th Edition). American Society for Bone and Mineral Research, Washington DC, USA (2003).
57. Thomas MK, Lloyd-Jones DM, Thadhani RI et al: Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338, 777-783 (1998).
58. Pascussi JM, Robert A. Nguyen M et al.: Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 115, 177-186 (2005).
59. Holick MF: Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J. Clin. Invest. 115, 32-34 (2005).
60. Koch HU, Kraft D, von Herrath D, Schaefer K: Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 13, 829-834 (1972).
61. Onodera K, Takahashi A, Sakurada S, Okano Y: Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci. 70, 1533-1542 (2002).
62. Stoffel-Wagner B, Bauer J, Flugel D, Brennemann W, Klingmuller D, Elger CE: Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia 39, 1164-1173 (1998).
63. Rattya J, Turkka J. Pakarinen AJ et al.: Reproductive effects of valproate, carbarmazepine, and oxcarbazepine in men with epilepsy. Neurology 56, 31-36 (2001).
64. Morrell MJ, Flynn KL, Seale CG et al.: Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr. 6, 771-772, 783-786 (2001).
65. Kuhn-Velten WN, Herzog AG, Muller MR: Acute effects of anticonvulsant drugs on gonadotropin-stimulated and precursor-supported androgen production in the rat testis. Eur. J. Pharmacol. 181, 151-155 (1990).
66. Isojarvi JI, Pakarinen AJ, Ylipalosaari PJ, Myllyla VV: Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch. Neurol. 47, 670-676 (1990).
67. Rattya J, Pakarinem AJ, Knip M, Repo-Outakoski M, Myllila VV, Jllsojarvi T: Early hormonal changes during valproate or carbamazepine treatment: a 3-months study. Neurology 57(3), 440-444 (2001).
68. Duncan S, Blacklaw J, Beastall GH, Brodie MJ: Antiepileptic, drug therapy and sexual function in men with epilepsy. Epilepsia 40(2), 197-204 (1999).
69. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329(19), 1383-1388 (1993).
70. Yanase T, Suzuki S, Goto K et al.: Aromatase in bone: roles of Vitamin D3 and androgens. J. Steroid Biochem. Mol. Biol. 86, 393-397 (2001).
71. Drezner MK: Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav. 5(Suppl. 2), S41-S47 (2004).
72. Nashef L, Lamb E: Vitamin D deficiency - guidelines are needed for treating diseases of bone metabolism in epilepsy. Br. Med. J. 318, 1285 (1999).